Geneva, June 16 -- International Clinical Trials Registry received information related to the study (NCT07004075) titled 'FCN-159 Monotherapy Versus Chemotherapy by Investigator's Choice in Pediatric Low-grade Glioma Patients With BRAF Alteration' on June 3.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Condition:
Low-grade Glioma
Pediatric Low-grade Gliomas
pLGG With BRAF Alteration
Intervention:
Drug: Luvometinib
Recruitment Status: Not recruiting
Phase: Phase 3
Date of First Enrollment: June 30, 2025
Target Sample Size: 102
Cou...